Business
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development - - Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement
About this update from Solid Biosciences Inc.
[{"type":"image","alt":"Solid Biosciences Inc.","displaySize":"","headline":null,"caption":"Solid Biosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/5e97e2fffdb55638e3c89b04065944ef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CN5B_bFXVU.yT4eUnV8MYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/5e97e2fffdb55638e3c89b04065944ef","width":300,"height":169},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/CN5B_bFXVU.yT4eUnV8MYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/5e97e2fffdb55638e3c89b04065944ef","width":300,"height":169}},"lazy":false},{"type":"text","content":"- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -","length":324,"tagName":"p"},{"type":"text","content":"- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -","length":258,"tagName":"p"},{"type":"text","content":"- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON clinical trial; SGT-212 has been well tolerated with no serious adverse events observed -","length":175,"tagName":"p"},{"type":"text","content":"- CPVT (SGT-501): Company anticipates dosing the first participant in the Phase 1b ARTEMIS clinical trial evaluating SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) in H2 2026 -","length":224,"tagName":"p"},{"type":"text","content":"- Capital Position: Cash, cash equivalents and available-for-sale securities of $380.7 million at March 31, 2026; the Company’s cash runway is anticipated to extend into H1 2028 -","length":179,"tagName":"p"},{"type":"text","content":"CHARLESTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medic...